Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: olaussen ka. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
Cyclooxygenase-2 as a target for anticancer drug development.
Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Méric JB, et al. Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64. doi: 10.1016/j.critrevonc.2006.01.003. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531064 Review.
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC; IALT Bio Investigators. Olaussen KA, et al. N Engl J Med. 2006 Sep 7;355(10):983-91. doi: 10.1056/NEJMoa060570. N Engl J Med. 2006. PMID: 16957145 Free article. Clinical Trial.
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.
de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, Lazar V, Dessen P, Harper F, Pierron G, Pinna G, Araujo N, Harel-Belan A, Armand JP, Wong TW, Soria JC, Kroemer G. de La Motte Rouge T, et al. Among authors: olaussen ka. Cancer Res. 2007 Jul 1;67(13):6253-62. doi: 10.1158/0008-5472.CAN-07-0538. Cancer Res. 2007. PMID: 17616683
MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.
Kamal NS, Soria JC, Mendiboure J, Planchard D, Olaussen KA, Rousseau V, Popper H, Pirker R, Bertrand P, Dunant A, Le Chevalier T, Filipits M, Fouret P; International Adjuvant Lung Trial-Bio investigators. Kamal NS, et al. Among authors: olaussen ka. Clin Cancer Res. 2010 Feb 15;16(4):1206-15. doi: 10.1158/1078-0432.CCR-09-2204. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145178
Validation of ERCC1-XPF immunodetection--letter.
Olaussen KA, Soria JC. Olaussen KA, et al. Cancer Res. 2010 May 1;70(9):3851-2; author reply 3852. doi: 10.1158/0008-5472.CAN-09-4352. Epub 2010 Apr 20. Cancer Res. 2010. PMID: 20406965 No abstract available.
58 results